Mankind Pharma eyes acquisition of biotech firms, plans new launches

Mankind became the first Indian and second global company to develop a dydrogesterone containing drug for treatment of pregnancy-related complications

Mankind Pharma is actively looking for buyouts in the biotechnology space after talks with Bharat Serums and Vaccines fell through. The company feels that a manufacturing site would be crucial for its biotechnology business and is open to inorganic acquisition in this space. 

"For the biotechnology segment we are open to inorganic growth. We are looking to acquire a suitable target that would bring in brands as well as manufacturing sites. We plan to launch biotech products in the infertility segment. We were in talks with Bharat Serums, but the talks fell through," said RC Juneja, founder and chairman of Mankind